Reviva pharmaceuticals holdings, inc. reports full year 2022 financial results and recent business highlights

- topline data for pivotal phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 –

RVPH Ratings Summary

RVPH Quant Ranking